Trials / Completed
CompletedNCT01417143
Dovitinib in Adenoid Cystic Carcinoma
Phase II Study of TKI258 (Dovitinib) Monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 33 (estimated)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this phase II study of TKI258 (Dovitinib) in adenoid cystic carcinoma is to evaluate the efficacy of TKI258 (Dovitinib).
Detailed description
open, uncontrolled, multi-center, phase II study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TKI258 (Dovitinib): | TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off schedule. TKI258 (Dovitinib) will be provided by Norvatis for the study purpose. One cycle consists of 4 weeks |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2013-12-01
- Completion
- 2014-11-01
- First posted
- 2011-08-16
- Last updated
- 2014-11-13
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01417143. Inclusion in this directory is not an endorsement.